Treatment of Parkinson’s Disease with Energy Healing
Printable version of “Treatment of Parkinson’s Disease with Energy Healing”
To save file, right click and choose “Save As”
*Requires Adobe Acrobat to view. CLICK HERE to download Adobe Acrobat Reader.
This article is a new look at Parkinson’s disease, can effectively be treated with energy healing?
By Aimee W. De Barbieri Lic. Ac
According to the Parkinson’s disease Foundation 1 to 1.5 million Americans suffer from Parkinson’s disease, and each year approximately 40,000 more Americans are diagnosed with this illness. Parkinson’s disease is a disorder most commonly affecting people over the age of 50 and is characterized by hypokinesia, the slowing down of movements. When we consult our neuroscience textbooks we find that most patients with Parkinson’s have lost more than 80% of the dopamine-utilizing neurons in their substantia nigra. Anatomically locating this influential part of the brain becomes important as we look to clinically treat and restore function in this area.
The characteristics of Parkinson’s are related to an increased inhibition of the thalamus by the basal ganglia causing a paucity of movement, whereas decreased basal ganglia output leads to the opposite, an excess of movement. According to the neuroscience and anatomy textbooks Parkinson’s disease is considered a basal ganglia disorder due to the degeneration of neurons that extend from the substantia nigra to the basal ganglia. Our treatment focuses on this degenerated area.
The symptoms of this disorder include slowness of movement (bradykinesia), difficulty in initiating willed movements (akinesia), increased muscle tone (rigidity), and tremors of the hands and jaw that are most prominent at rest. The basis of this degenerative disease takes place in the substantia nigra where there is a breakdown in this part of the brain’s ability to input to the striatum. These inputs use the neurotransmitter dopamine (DA) to facilitate the direct motor loop by activating cells in the putamen. The depletion of dopamine closes the funnel that feeds activity to SMA via the basal ganglia. However, what do we do when there is a sufficient amount of dopamine, yet the Parkinson’s symptoms do not resolve? In many cases, dopamine is supplied to the patient but their symptoms remain. We must consider that the biochemical function is doing well, but that neurologically the signals are still not passing sufficiently.